Closing of the donut hole could conceivably prove to be a net positive for Big Pharma if it can significantly increase medication compliance for patients with such “asymptomatic” chronic conditions as hypertension and dyslipidemia. The article in #msg-48270329 speaks to this point.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”